|
【结 构 式】 
|
【药物名称】Pyroxamide, NSC-696085 【化学名称】N'-Hydroxy-N-(3-pyridyl)octane-1,8-diamide 【CA登记号】382180-17-8 【 分 子 式 】C13H19N3O3 【 分 子 量 】265.31468 |
【开发单位】National Cancer Institute (Originator) 【药理作用】ONCOLYTIC DRUGS, Histone Deacetylase (HDAC) Inhibitors |
合成路线1
Monomethyl suberate (I) is treated with isobutyl chloroformate to produce the mixed anhydride (II), which is subsequently coupled with 3-aminopyridine (III), yielding amide (IV). The methyl ester group of (IV) is finally converted to the target hydroxamate upon treatment with methanolic hydroxylamine.
| 【1】 Gilbert, J.; et al.; A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res 2001, 7, 8, 2292. |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (I) | 56374 | Methyl hydrogen octane-1,8-dioate; Monomethyl suberate; Octanedioic acid monomethyl ester; Suberic acid monomethyl ester | 3946-32-5 | C9H16O4 | 详情 | 详情 |
| (II) | 56375 | C14H24O6 | 详情 | 详情 | ||
| (III) | 33327 | 3-Pyridinylamine; 3-Aminopyridine; 3-Pyridinamine | 462-08-8 | C5H6N2 | 详情 | 详情 |
| (IV) | 56376 | methyl 8-oxo-8-(3-pyridinylamino)octanoate | C14H20N2O3 | 详情 | 详情 |
Extended Information